Free Trial

EKF Diagnostics (EKF) Competitors

EKF Diagnostics logo
GBX 27
-0.70 (-2.53%)
(As of 11/1/2024 ET)

EKF vs. MXCT, NIOX, CREO, NCYT, IUG, BELL, POLX, IHC, AVO, and RUA

Should you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include MaxCyte (MXCT), NIOX Group (NIOX), Creo Medical Group (CREO), Novacyt (NCYT), Intelligent Ultrasound Group (IUG), Belluscura (BELL), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.

EKF Diagnostics vs.

EKF Diagnostics (LON:EKF) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -77.97%. EKF Diagnostics' return on equity of 7.58% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics9.37% 7.58% 5.27%
MaxCyte -77.97%-15.33%-11.07%

EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.

CompanyUnderperformOutperform
EKF DiagnosticsOutperform Votes
327
76.76%
Underperform Votes
99
23.24%
MaxCyteOutperform Votes
153
68.92%
Underperform Votes
69
31.08%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
MaxCyte
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

EKF Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£50.95M2.40£4.78M£0.012,700.00
MaxCyte£45.44M6.54-£35.43M-£0.26-1,088.46

70.3% of EKF Diagnostics shares are held by institutional investors. Comparatively, 70.5% of MaxCyte shares are held by institutional investors. 5.2% of EKF Diagnostics shares are held by company insiders. Comparatively, 1.5% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

EKF Diagnostics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

In the previous week, MaxCyte had 3 more articles in the media than EKF Diagnostics. MarketBeat recorded 3 mentions for MaxCyte and 0 mentions for EKF Diagnostics. MaxCyte's average media sentiment score of 0.47 beat EKF Diagnostics' score of 0.15 indicating that MaxCyte is being referred to more favorably in the news media.

Company Overall Sentiment
EKF Diagnostics Neutral
MaxCyte Neutral

Summary

EKF Diagnostics beats MaxCyte on 10 of the 15 factors compared between the two stocks.

Get EKF Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EKF vs. The Competition

MetricEKF DiagnosticsMedical Devices IndustryMedical SectorLON Exchange
Market Cap£122.51M£1.99B£5.40B£1.59B
Dividend Yield4.65%2.49%5.15%10.99%
P/E Ratio2,700.00206.74113.761,747.90
Price / Sales2.40208.831,483.04231,381.08
Price / Cash10.6416.0539.7136.00
Price / Book1.803.244.662.89
Net Income£4.78M£70.94M£119.06M£144.83M
7 Day Performance0.56%-1.98%0.79%0.11%
1 Month Performance-12.62%-3.94%5.65%-0.11%
1 Year Performance-1.82%35.59%36.80%15.34%

EKF Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EKF
EKF Diagnostics
N/AGBX 27
-2.5%
N/A-4.7%£122.51M£50.95M2,700.00356Gap Up
MXCT
MaxCyte
N/AGBX 285
-2.1%
N/A+15.9%£299.51M£45.44M-1,096.1580News Coverage
NIOX
NIOX Group
N/AGBX 61.80
-0.3%
N/A-2.1%£262.11M£39M3,090.0092Gap Up
CREO
Creo Medical Group
N/AGBX 20
flat
N/A-38.5%£72.36M£30.30M-333.33279Positive News
NCYT
Novacyt
N/AGBX 54.90
-2.8%
N/A+19.1%£38.78M£18.56M-105.58120Gap Up
IUG
Intelligent Ultrasound Group
N/AGBX 11.10
-0.2%
N/A+28.0%£36.30M£9.88M-1,110.0065
BELL
Belluscura
N/AGBX 10.13
-11.9%
N/A-64.7%£17.07M£1.80M-101.3324Gap Down
POLX
Polarean Imaging
N/AGBX 1.40
+3.7%
N/A-80.6%£16.94M£1.87M-70.0028Gap Up
IHC
Inspiration Healthcare Group
N/AGBX 16.50
flat
N/A-55.0%£14.79M£34.30M-117.86224News Coverage
AVO
Advanced Oncotherapy
N/AGBX 1.75
-9.1%
N/A+0.0%£9.50MN/A-25.003,900Gap Down
RUA
RUA Life Sciences
N/AGBX 12.70
+1.1%
N/A+2.6%£7.88M£2.19M-317.5048Gap Up

Related Companies and Tools


This page (LON:EKF) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners